Background
Boston Heart Diagnostics (BHD) is a laboratory company that develops blood lipid tests for diagnosing heart disease. In 2015, BHD partnered with Little River Health Care, a critical-access hospital system in rural Texas operating two hospitals that, under Medicare regulations, received cost-based reimbursements significantly exceeding standard rates. The defendants—Hertzberg (BHD CEO), Theiler (VP of Sales), Kraus and Hardaway (sales representatives)—allegedly orchestrated a scheme to capitalize on Little River’s favorable reimbursement rates by recruiting affiliated physicians to refer patients to the hospital for testing.
The scheme operated through pass-through entities called Management Service Organizations (MSOs). According to the government’s theory, MSO “marketers” recruited physicians to partner with Little River, ostensibly providing marketing and administrative services. In reality, the evidence suggested physicians were paid kickbacks based on referral volumes, disguised as compensation for these purported services. BHD’s sales team worked directly with MSO marketers to recruit physicians and manage referral volumes. From April 2015 to June 2016, the partnership generated approximately $20.5 million in revenue for BHD—representing a quarter of projected nationwide annual revenue for a single rural hospital. Average test reimbursements from Little River doubled from around $400 to $942, compared to BHD’s national average of $370. The defendants concealed the scheme through sham contracts and false attestations that MSO payments were not tied to referrals of federally-insured patients.
A grand jury indicted eighteen defendants in January 2022. Four defendants—Hertzberg, Hardaway, Theiler, Kraus, and Madison (Little River’s CEO)—proceeded to joint trial in October-November 2023. The jury returned guilty verdicts on conspiracy charges for all. The non-Madison defendants appealed, challenging the sufficiency of evidence, the court’s handling of jury notes, and the denial of a good-faith jury instruction.
The Court’s Holding
The Fifth Circuit affirmed all convictions under the Anti-Kickback Statute conspiracy provision. On the sufficiency of evidence, the court found that a rational jury could infer each defendant knowingly joined the conspiracy based on circumstantial evidence. For Hertzberg specifically, the court emphasized her position as an experienced healthcare CEO, her prior 2011 report to DOJ of a competitor lab’s similar kickback scheme, her awareness of the extraordinarily high profit margins and reimbursement rates from Little River, her proximity to the fraudulent activities, her involvement in expanding the scheme to other hospitals, and her failure to report a whistleblower complaint to authorities—instead questioning the whistleblower and transferring him to an unrelated role. The court found her actions in limiting distribution of Little River financial data and interrupting a board presentation about MSO recruitment particularly telling of guilty knowledge.
Regarding the jury-note issue, defendants argued the court erred by not immediately disclosing and responding to a second jury note indicating juror #12 was unwilling to change his mind and would “hang the jury.” The Fifth Circuit held that defendants forfeited the claim by failing to object or move for mistrial when note #4 was disclosed after the verdict. Even applying plain-error review, the court found no error warranting reversal—the trial court’s instruction to continue deliberating in good faith was proper, and the jury ultimately returned a unanimous guilty verdict that was affirmed upon polling.
Finally, the court rejected Hardaway’s proposed jury instruction that good faith is a complete defense to conspiracy charges. The court found the instruction unnecessary because good faith was adequately addressed through the knowledge and willfulness elements already in the jury charge, which properly required proof the defendant knowingly and willfully agreed to participate in illegal remuneration.
Key Takeaways
- The Anti-Kickback Statute applies to payments disguised as compensation for services when they actually incentivize physician referrals, and does not require proof the defendant knew patients would actually be federally insured—only that referrals were for patients who “could be” federally insured.
- Senior management can face conspiracy liability based on circumstantial evidence, including awareness of suspicious profit margins, position of authority, proximity to fraudulent activities, engagement in concealment, and failure to address employee concerns or report suspicious conduct.
- Courts apply highly deferential review to jury verdicts on sufficiency-of-the-evidence challenges, requiring only that any rational jury could have found guilt beyond a reasonable doubt based on circumstantial evidence and reasonable inferences.
- Jury-management claims are forfeited if defendants fail to object or request a mistrial when jury notes are disclosed, even if the trial court did not respond to all notes before rendering verdict.
Why It Matters
This decision reinforces the government’s broad enforcement authority under the Anti-Kickback Statute against laboratory companies, hospital networks, and intermediary entities like MSOs that facilitate physician recruitment tied to referral volumes. The case illustrates that courts will infer conspiracy and guilty knowledge from business circumstances alone—explosive revenue growth, unusually high reimbursement rates, and the involvement of recruitment entities—without requiring direct evidence of explicit agreements to pay kickbacks. Notably, the court emphasized that even an experienced healthcare executive’s awareness that a competitor lab faced DOJ investigation for similar conduct can support an inference of guilty knowledge when facing similar fact patterns.
For healthcare providers and laboratory companies, the decision underscores the risks of clinical-access hospital partnerships structured around physician recruitment through intermediary MSOs, and the importance of robust, independent compliance infrastructure. The court also suggested that executive responses to whistleblower complaints—including questioning complainants or reassigning them—may constitute evidence of consciousness of guilt. Senior executives cannot rely on financial analysts’ lack of suspicion or claimed confusion about business models to defeat conspiracy charges when the facts show awareness of unusual profitability and involvement in structuring referral arrangements.